Naureen Quibria

Stock Analyst at Capital One

(n/a)

# 4,465

Out of 4,883 analysts

9

Total ratings

11.11%

Success rate

-44.95%

Average return

Main Sectors:

Top Industries:

Stocks Rated by Naureen Quibria

	Stock	Action	Price Target	Current	Upside	Ratings	Updated
	BMEA Biomea Fusion	Initiates: Overweight	$25	$1.66	+1,406.02%	1	Aug 29, 2024
	IMMP Immutep	Initiates: Overweight	$10	$1.72	+481.40%	1	May 17, 2024
	ERAS Erasca	Initiates: Overweight	$8	$1.44	+455.56%	1	Mar 11, 2024
	CARM Carisma Therapeutics	Initiates: Overweight	$10	$0.40	+2,381.39%	1	Oct 3, 2023
	IMCR Immunocore Holdings	Initiates: Overweight	$84	$33.02	+154.39%	1	Aug 16, 2023
	DAWN Day One Biopharmaceuticals	Initiates: Overweight	$40	$6.80	+488.24%	1	Feb 8, 2023
	FENC Fennec Pharmaceuticals	Initiates: Overweight	$11	$8.80	+25.00%	1	Sep 7, 2022
	GNTA Genenta Science	Initiates: Buy	$21	$3.80	+452.63%	1	Jan 13, 2022
	KZIA Kazia Therapeutics	Initiates: Buy	$900	$6.75	+13,233.33%	1	Oct 14, 2021

Biomea Fusion

Aug 29, 2024

Initiates: Overweight

Price Target: $25

Current: $1.66

Upside: +1,406.02%

Immutep

May 17, 2024

Initiates: Overweight

Price Target: $10

Current: $1.72

Upside: +481.40%

Erasca

Mar 11, 2024

Initiates: Overweight

Price Target: $8

Current: $1.44

Upside: +455.56%

Carisma Therapeutics

Oct 3, 2023

Initiates: Overweight

Price Target: $10

Current: $0.40

Upside: +2,381.39%

Immunocore Holdings

Aug 16, 2023

Initiates: Overweight

Price Target: $84

Current: $33.02

Upside: +154.39%

Day One Biopharmaceuticals

Feb 8, 2023

Initiates: Overweight

Price Target: $40

Current: $6.80

Upside: +488.24%

Fennec Pharmaceuticals

Sep 7, 2022

Initiates: Overweight

Price Target: $11

Current: $8.80

Upside: +25.00%

Genenta Science

Jan 13, 2022

Initiates: Buy

Price Target: $21

Current: $3.80

Upside: +452.63%

Kazia Therapeutics

Oct 14, 2021

Initiates: Buy

Price Target: $900

Current: $6.75

Upside: +13,233.33%